HEALTH● LOW1h ago · Oct 25, 2026, 4:17 PM
AstraZeneca stomach cancer drug doubles survival in late-stage trial
Seeking Alpha Tech · global
AstraZeneca's stomach cancer drug has shown to double survival rates in a late-stage trial, indicating a significant advancement in cancer treatment. This development could offer a new therapeutic option for patients battling stomach cancer.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH1h agoEbola: NCDC tracks 53 contacts, orders hospitals to isolate suspectsVanguard NigeriaHEALTH1h agoNCDC approves N100,000 weekly stipend for Ebola contactsVanguard NigeriaHEALTH1h agoEbola: 53 Contacts, Including Healthcare Workers Under Surveillance, Says NCDCChannels TVHEALTH1h agoProtein shakes for teenagers: Good or bad idea?DW News [en]